High cellular heterogeneity makes cancer treatment more challenging. BGI Genomics researchers have leveraged the spatial transcriptomic (ST) method to profile tumor microenvironment in breast cancer.

Learn more 

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July of 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.